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Abstract

Statement of the Problem

Literature Review

• Atrial fibrillation increases in occurrence as we age with about
9% of patients developing it by age 90. When a patient is
diagnosed with atrial fibrillation, one of the drugs that they are
prescribed is an anticoagulant. The purpose of this drug is to
prevent thrombus formation in addition to preventing an
ischemic stroke. Today, there are many options available for
anticoagulation therapy. The options include aspirin, vitamin K
antagonists like warfarin, factor Xa inhibitors like rivaroxaban
and apixaban, direct thrombin inhibitors like dabigatran, and
antiplatelet agents such as clopidogrel.
• A review of the literature was done of peer reviewed journal
articles using the databases PubMed, Dynamed, CINAHL and
Clinical Key. A total of 14 articles were used in this paper with
the inclusion criteria of being published within the past five
years, the patients all have atrial fibrillation, over 65 years old,
and are on some form of anticoagulation therapy.
• Previously, warfarin has been one of the few anticoagulation
drugs on the market until the newer novel anticoagulants were
released. Bell et al. (2016) found that warfarin is still used in
53.6% of the patients, even though the prevalence has decreased
by 3.9% between the years of 2011 and 2013. (p <.001)
• It was found that patients who were diagnosed with atrial
fibrillation needed some form of anticoagulation as compared to
no anticoagulation to reduce stroke. Most of the studies
compared warfarin versus no anticoagulation treatment. There
were not many studies that looked at the newer novel
anticoagulants. It was mentioned that there has been a decrease
in warfarin use since the newer novel anticoagulants have been
released. There are considerations that a prescriber needs to be
conscious of before prescribing a specific anticoagulant. Some
of these considerations are renal function, other medication
usage to avoid drug-drug interactions and age.

With increases of Atrial Fibrillation as a person ages, studies
are needed to show if the new oral anticoagulants are superior
to warfarin.

• Ng et al. (2015) did a subgroup analysis of the AVERROES trial
determines that patients over 85 had less risk of hemorrhagic
bleeding when on apixaban compared to aspirin.
• A study done by Yamashita et al. (2016) determined that in the
elderly over 85, stroke risk increased whether the patient was on
anticoagulation or not.
• An analysis looked at the ROCKET AF study done by Hankey et
al. (2014) evaluated the risk of intracranial hemorrhage
comparing warfarin versus rivaroxaban. They found that there
was no major different of intracranial hemorrhage between these
two medications.
• Staerk et al. (2016) did a study using the RE-LY, ATRISOTLE, and
AVERROES trials to study the different anticoagulation therapies.
They found that the new novel anticoagulants continue to rise in
use, but warfarin is still superior in patients with renal failure.
• An analysis done by Piccini et al. (2016) used the ROCKET AF
study to look at the effects that multiple medications had on the
use of warfarin or rivaroxaban in patients with atrial fibrillation.
They found that as the number of multiple medications
increases, so does the chance of bleeding in patients with atrial
fibrillation.

Introduction
Atrial fibrillation is the most prevalent cardiac arrhythmia
worldwide, which is diagnosed in many patients each day and
increases as a patient ages. Anticoagulation therapy is a major part
of treating the patient and there are many anticoagulants to choose
from. The options include aspirin, vitamin K antagonist like
warfarin, factor Xa inhibitors like rivaroxaban and apixaban, direct
thrombin inhibitors like dabigatran, and antiplatelet agent such as
clopidogrel. All of the different types of anticoagulation options
can make treatment quite difficult given the diversity. The purpose
of this study is to determine what anticoagulants are most effective
in preventing clot formation that could lead to a stroke, but have
the lowest occurrence of adverse effects such as fatal bleeding.
With atrial fibrillation becoming increasingly more prevalent as a
person ages and the many options available for anticoagulation, it
can be difficult to decide which anticoagulant is most appropriate.

Research Question
In patient diagnosed with Atrial Fibrillation, is there an
anticoagulation therapy that is superior to the others for use in the
elderly?

Applicability to Clinical
Practice
When a patient is diagnosed with a new disease, there needs to
be a conversation between the provider and the patient. With
the addition of atrial fibrillation as a diagnosis to their list of
previous diagnoses, the provider and the patient need to sit
down and discuss the patient’s options. Together they need to
decide which anticoagulant would be the best for that specific
patient both for the health of the patient, to make sure it is a
medication the patient will be willing to adhere to and make sure
they are able to afford the medication. Patients see many new
advertisements for the newer novel anticoagulation therapies
without fully understanding the difference between the different
types of drugs. It is the job of the provider to explain the
differences between the anticoagulants, so they can come up
with a regimen that works best for the patient regarding their age,
renal function, bleeding and stroke history, and the amount of
medications they are on. With this communication between
provider and patient, hopefully there will be an increase in
compliance of anticoagulant use as well as a decrease in the
amount of ischemic strokes in patients with atrial fibrillation.
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Pathophysiology

Discussion

The heart contracts due to electrical impulses or action potentials
that travel from the sinoatrial (SA) node to the atrioventricular (AV)
node. The action potentials travel from the SA node through the
myocardium of the atrium and cause a contraction. In a patient
with atrial fibrillation, these electrical impulses become
unorganized and result in multiple stimulations of the
myocardium, which causes the atrium to contract in an
uncoordinated fashion. This uncoordinated contraction leads to the
atrium being unable to fully contract and empty blood from the
chambers. This can leave blood in the atrium and this blood can
start to clot, which could then travel to the brain and cause a
stroke.

• Atrial fibrillation is a common disease that people are diagnosed
with more and more as they age. There are many different
medications that are prescribed when a diagnosis of atrial
fibrillation is made. One of the new additions to their
medication regimen is an anticoagulant.
• Previously, warfarin had been the anticoagulant of choice and
most people had been placed on warfarin for ischemic stroke
prophylaxis. There are many things to consider when choosing
an anticoagulant. While on warfarin patients need to have blood
tested regularly to make sure it maintains at recommended
levels. Warfarin does take more time to get to a therapeutic level
and can be very difficult to keep patients at this acceptable level.
There are also many interactions with different drugs and even
certain foods.
• The new addition of the novel oral anticoagulant agents is
appealing to both patients and providers. With this medication,
the patient does not have to have blood drawn multiple times a
week to check their therapeutic level. The downside to these
medications with them being newer, is their cost and they
should not be used in patients with renal impairment. Many of
the patients with atrial fibrillation taking anticoagulant therapy
are elderly and cannot afford the new novel oral anticoagulants.
The prescriber needs to consider the patient’s current
medication list, their renal function as well as if the patient will
be able to afford the medication.
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